Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions

CDH17-positive Advanced Solid Tumors

Interventions

BIOLOGICAL

Anti-CDH17 CAR-T cells infusion

Subiects who meet the enrollment conditions will receive intravenous infusion of anti-CDH17 CAR-T Cells after lymphodepleting therapy.

Trial Locations (1)

RECRUITING

Sanbin Wang, Kunming

All Listed Sponsors

collaborator

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY

lead

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER